U.S. Ophthalmic Disease Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Anti-inflammatory, Anti-infectives, Anti-VEGF, Anti-glaucoma {Beta Blockers, Prostaglandins Analogs, Alpha Adrenergic Agonists}), By Dosage Form (Solid, Liquid, and Semisolid), By Disease Indication (Glaucoma {Open Angle Glaucoma, Angle Closure Glaucoma}, Dry Eye Disease, Retinal Diseases {Diabetic Macular Edema, Macular Degeneration, Diabetic Retinopathy}, Allergy & Infections), By Distribution Channel (Hospital Pharmacies, Retail & Online Pharmacies), and Country Forecast, 2023-2030

Last Updated: November 24, 2025 | Format: PDF | Report ID: FBI108840

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2023
Forecast Period	2023-2030
Historical Period	2019-2021
Growth Rate	CAGR of 6.5% from 2023 to 2030
Unit	Value (USD Billion)
Segmentation	By Drug Class Anti-inflammatory Anti-infectives Anti-VEGF Anti-glaucoma Beta Blockers Prostaglandins Analogs Alpha Adrenergic Agonists Carbonic Anhydrase Inhibitors Combination Drugs Others Others
	By Dosage Form Solid Liquid Semisolid
	By Disease Indication Glaucoma Open Angle Glaucoma Angle Closure Glaucoma Others Dry Eye Disease Retinal Diseases Diabetic Macular Edema (DME) Macular Degeneration (AMD) Diabetic Retinopathy (DR) Retinal Vein Occlusion (RVO) Others Allergy & Infections Others
	By Distribution Channel Hospital Pharmacies Retail & Online Pharmacies